Generation Bio Co., a genetic medicines company, develops therapies for the treatment of rare and prevalent diseases. Generation Bio was incorporated in 2016 and is headquartered in Cambridge, Massachusetts. Generation Bio employs 115 people. Headquarters are in 301 Binney Street, Cambridge, MA, United States, 02142. Current valuation profile shows market cap 35.98 million, P/B 0.71, P/S 2.36. As a micro-cap equity, Generation Bio is evaluated across valuation, solvency, and efficiency signals. Financial reporting is combined with risk and trading context. The company is currently operating at a loss.
Methodology
Unless otherwise specified, financial data for Generation Bio Co is derived from periodic company reporting (annual and quarterly where available). Asset-level metrics are computed daily by Macroaxis LLC and refreshed regularly based on asset type. Generation Bio (USA Stocks:GBIO) prices are typically delayed by approximately 20 minutes from primary exchanges for listed equities. Data may be delayed depending on reporting sources and market conventions. All analytics presented are generated using Macroaxis quantitative models that incorporate financial statement analysis, market data, and risk metrics to ensure consistency and comparability. Assumptions: We use public filings and market reference sources with disclosures published by U.S. Securities and Exchange Commission (SEC) via EDGAR as reference inputs. Data may be normalized and can be delayed. All analytics are generated using standardized, rules-based models designed to promote consistency and comparability across instruments. Model assumptions, reference parameters, and selected computational inputs are available in the Model Inputs section. If you have questions about our data sources or methodology, please contact Macroaxis Support.
Analyst Sources
Generation Bio Co may have analyst coverage included in Macroaxis-derived consensus inputs when available. Updates may occur throughout the day.
Editorial review and methodology oversight provided by:
Michael Smolkin, Member of Macroaxis Board of Directors
These listed companies frame Generation Bio's former industry context and operating niche. For a delisted instrument, comparable peers are more useful for sector reference than for direct trading signals or return forecasting.
This summary explains why delisted instruments usually require a different level of diligence than listed securities. It focuses on venue risk, disclosure gaps, and the challenge of exiting a position efficiently. Investing in delisted stocks can be risky, as the stock is no longer traded on a public exchange and can therefore be difficult to sell. Delisting typically occurs when a company has failed to meet exchange requirements or has been acquired. Before investing, it's important to thoroughly research the company, including its financial health and prospects for the future, as well as the reasons for its delisting. Additionally, it may be difficult to find accurate and up-to-date information on the company and its stock.
Generation Bio has a market cap of 35.98 million, an operating margin of -20.2% (TTM), current ratio of 17.93. Margin expansion paired with stable liquidity is generally a constructive signal. Broader economic conditions can influence Generation Bio Co's company valuation - related indicators include
signals in gross domestic product.
Generation Bio currently shows ROE of -80.81%, market cap of USD 35.98 million. Generation Bio analysis is best paired with portfolio risk and diversification tools before adjusting allocations. A thorough Generation Bio review pairs the data above with the quantitative and comparative resources listed below. You can also try the
Bollinger Bands module to use Bollinger Bands indicator to analyze target price for a given investing horizon.
OTC-traded securities such as Generation Bio require careful evaluation of reporting standards.